



Europäisches Patentamt  
European Patent Office  
Office européen des brevets

(11) Publication number:

0 224 924  
A2

(12)

## EUROPEAN PATENT APPLICATION

(21) Application number: 86116853.2

(51) Int. Cl.: C 07 C 87/26

(22) Date of filing: 04.12.86

C 07 C 85/20, C 07 C 149/24  
C 07 C 147/04, A 61 K 31/13

(30) Priority: 05.12.85 US 805506  
05.12.85 US 806162

(71) Applicant: MERRELL DOW PHARMACEUTICALS INC.  
2110 E. Galbraith Road  
Cincinnati Ohio 45215(US)

(43) Date of publication of application:  
10.06.87 Bulletin 87/24

(72) Inventor: Bey, Philippe  
7875 Ivy Gate Lane  
Cincinnati Ohio 45242(US)

(84) Designated Contracting States:  
AT BE CH DE ES FR GB GR IT LI LU NL SE

(72) Inventor: Palfreyman, Michael G.  
11515 Applejack Court  
Cincinnati Ohio 45249(US)

(72) Inventor: McDonald, Ian A.  
9382 Kentonrun Court  
Loveland Ohio 45140(US)

(74) Representative: Vossius & Partner  
Siebertstrasse 4 P.O. Box 860767  
D-8000 München 86(DE)

(54) Non-aromatic fluorallylamine MAO inhibitors.

(57) Novel nonaromatic fluoroallylamines are potent MAO inhibitors and at low dose selectively inhibit MAO-B. They are useful in the treatment of depression and co-administered with L-dopa, in the treatment of Parkinsonism.

EP 0 224 924 A2

# VOSSIUS & PARTNER

PATENTANWALTE  
EUROPEAN PATENT ATTORNEYS

0224924

Dr. VOLKER VOSSIUS, Dipl.-Chem.  
DOROTHEA VOSSIUS, Dipl.-Chem.  
Dr. PAUL TAUCHNER, Dipl.-Chem.  
Dr. DIETER HEUNEMANN, Dipl.-Phys.  
Dr. PETER RAUH, Dipl.-Chem.  
Dr. GERHARD HERMANN, Dipl.-Phys.

SIEBERTSTRASSE 4  
P.O.BOX 860767  
8000 MÜNCHEN 86  
PHONE: (089) 474075  
CABLE: BENZOLPATENT MÜNCHEN  
TELEX: 529453 VOPAT-D  
TELEFAX: (089) 472001 (GR. II + III)

Our ref.: W 024 EP  
Case: C-34,714 EP  
MERRELL DOW PHARMACEUTICALS INC.

04. Dez. 1986

## NONAROMATIC FLUOROALLYLAMINE MAO INHIBITORS

This invention relates to novel chemical compounds and to methods of treatment employing these compounds.

5       The class of compounds known as monoamine oxidase inhibitors (MAO inhibitors) has been employed in psychiatry for over twenty years for the treatment of depression [See Goodman and Gilman, The Pharmacological Basis of Therapeutics, 6th Ed., McMillan Publishing Co., Inc., N.Y., 10 1980, pages 427-430]. MAO inhibitors currently used in the United States for treating depression are tranylcypromine (PARNATE®, SKF), phenelzine (NARDIL®, Parke-Davis), and isocarboxazid (MARPLAN®, Roche). In addition, another MAO inhibitor, pargyline (EUTRON®, Abbott), is available for 15 the treatment of hypertension [See Physicians' Desk Reference, 34th Ed., Medical Economics Co., Oradell, N.J., 1980, pages 1327-1328 (phenelzine), pages 1466-1468 (isocarboxazid), pages 1628-1630 (tranylcypromine), and pages 521-522 (pargyline)]. In addition to being used in

treating depression, MAO inhibitors can be employed to treat other psychiatric disorders, such as phobic anxiety states.

Parkinson's syndrome is characterized by low levels of dopamine in the brain. The disease can be treated by the administration of exogenous dopa (or preferably L-dopa) which passes through the blood-brain barrier into the brain where it is transformed to dopamine which replenishes the endogenous monoamine. Dopamine is itself not effective for treating Parkinson's syndrome since it is not transported across the blood-brain barrier. It is known that the coadministration of a peripherally active aromatic amino decarboxylase (AADC) inhibitor (such as carbidopa) with L-dopa potentiates the effect of L-dopa and provides effective therapy at a lower dose of L-dopa. (See Physician's Desk Reference, Medical Economics Co., Oradell, N.J. p. 1198-1199). The potentiation of L-dopa occurs because the AADC inhibitor prevents the peripheral decarboxylation of L-dopa thereby increasing the amount of circulating L-dopa available for absorption into the brain. Prevention of the peripheral decarboxylation of dopa will also decrease the amount of circulating dopamine which is responsible for undesirable side effects. It is also known that the coadministration of certain MAO inhibitors (such as L-deprenyl) with L-dopa potentiates the effect of L-dopa and also provides effective therapy at a lower dose of L-dopa because the MAO inhibitor prevents the oxidative deamination of dopamine upon its formation from L-dopa.

It is believed that the MAO inhibitors act to alleviate psychiatric disorders, such as depression, by increasing the concentration of one or more biogenic monoamines in the brain or sympathetic nervous system. The

monoamine oxidase enzyme (MAO) plays an important role in the metabolic regulation of the monoamines since it catalyzes the biodegradation of the monoamines through oxidative deamination. By inhibiting MAO, the degradation 5 of the monoamines is blocked, and the result is an increase in the availability of the monoamines for their physiological functions. Among the physiologically active monoamines which are known substrates for MAO are: (a) the so-called "neurotransmitter" monoamines, such as the 10 catecholamines (e.g. dopamine, epinephrine, and norepinephrine) and the indoleamines (e.g. tryptamine and 5-hydroxytryptamine), (b) the so-called "trace" amines (e.g.  $\alpha$ -tyramine, phenethylamine, tele-N-methylhistamine), and (c) tyramine.

15       The usefulness of the MAO inhibitors in treating depression is limited because the administration of such agents can potentiate the pharmacological actions of certain food substances or drugs leading to dangerous and sometimes lethal effects. For example, persons receiving a 20 MAO inhibitor must avoid the ingestion of foods which have a high tyramine content (such as cheese) because the MAO inhibitor will block the metabolic degradation of tyramine in the gut to produce high circulating levels of tyramine, consequent release of catecholamines in the periphery, and 25 finally serious hypertension. The potentiation by a MAO inhibitor of the pressor effect of tyramine arising from the ingestion of cheese, and the hypertensive episode produced thereby, are commonly known as the "cheese reaction" or "cheese effect". Moreover, persons on 30 conventional MAO therapy cannot be given directly-acting sympathomimetic drugs (or precursors thereof) which are themselves substrates for MAO (e.g. dopamine, epinephrine, norepinephrine, or L-DOPA) or indirectly-acting sympathomimetic drugs (e.g. amphetamines or cold, hay-

fever, or weight control preparations that contain a vasoconstrictor). The potentiation of the pressor effect of indirectly-acting sympathomimetic drugs is especially profound. This is because such drugs act peripherally primarily by releasing catecholamines in nerve endings, and the concentration of the liberated catecholamines will be dangerously elevated if the metabolic degradation of the catechoamines via MAO is blocked.


Biochemical and pharmacological studies indicate that the MAO enzyme exists in two forms known as "MAO Type A" (MAO-A) and "MAO Type B" (MAO-B). The two forms differ in their distribution in body organs, in their substrate specificity, and in their sensitivity to inhibitors. In general, MAO-A selectively oxidizes the so-called "neurotransmitter" monoamines (epinephrine, norepinephrine and 5-hydroxytryptamine) while MAO-B selectively oxidizes the "trace" monoamine ( $\alpha$ -tyramine, phenethylamine, and tele-N-methylhistamine). Both MAO-A and MAO-B oxidize tyramine, tryptamine, and dopamine. However, in man, dopamine has been shown to be a preferred substrate for MAO-B. The forms also differ in their sensitivity to inhibition, and thus they can be preferentially inhibited depending upon the chemical structure of the inhibitor and the enzyme. The MAO inhibitors currently sold in the United States for the therapy of depression (tranylcypromine, phenelzine, and isocarboxazid) are not preferential in their action upon MAO. However, various chemical compounds are known in the art to be preferential inhibitors of MAO, the most important being clorgyline, pargyline, and L-

deprenyl which are all reported to be clinically effective antidepressant agents. MAO-A is preferentially inhibited by clorgyline, while MAO-B is preferentially inhibited by pargyline and L-deprenyl. The selectivity of an inhibitor for MAO-A or MAO-B in vivo will be dose-dependent, selectivity being lost as the dosage is increased. Clorgyline, pargyline, and L-deprenyl are selective inhibitors at lower dosages, but are less selective inhibitors at higher dosages. The literature concerning MAO-A and MAO-B and the selective inhibition thereof is extensive [See, for example, Goodman and Gilman, ibid, pages 204-205; Neff et al., Life Sciences, 14, 2061 (1974); Murphy, Biochemical Pharmacology, 27, 1889 (1978); Knoll, Chapter 10, pages 151-171 and Sandler, Chapter 11, pages 173-181, in Enzyme Inhibitors as Drugs, M. Sandler, Ed., McMillan Press Ltd., London 1980; Lipper et al., Psychopharmacology, 62, 123 (1979); Mann et al., Life Sciences, 26, 877 (1980); and various articles in Monoamines Oxidase: Structure, Function, and Altered Functions, T. Singer et al. Ed., Academic Press. N.Y., 1979].

Of the selective inhibitors of MAO, L-deprenyl is of interest since the "cheese effect" is not observed at the low dosages where preferential inhibition of MAO-B occurs [See Knoll, TINS, pages 111-113, May 1979]. This observation is not unexpected since the intestinal mucosa contains predominantly MAO-A which, because it is not inhibited, permits oxidation and removal of the ingested tyramine. The selectivity of L-deprenyl for MAO-B may account for its ability to potentiate L-DOPA for the treatment of Parkinson's disease without producing peripheral side effects, such as hypertension due to potentiation of pressor catecholamines [See Kees et al., Lancet, pages 791-795, October 15, 1977 and Birkmeyer Lancet, pages 439-443, February 26, 1977].

Previously the presence of an aryl moiety was believed necessary for potent MAO inhibition in those compounds which structurally mimic phenylethylamine, serotonin, the catecholamines, indoleamines, and trace amines such as the 5 arylalkylhydrazines, propargylamines, phenylcyclopropylamines, and -methyltryptamines. Applicants have discovered a class of potent MAO inhibitors which do not structurally mimic the natural monoamines. In many cases, these novel, nonaromatic MAO inhibitors 10 selectively inhibit MAO-B at low doses.


The subject matter of the invention are fluoroallylamines of formula 1



wherein

R is hydrogen or a  $(\text{C}_1-\text{C}_4)$  alkyl;  
 n and m are each either zero or 1;  
 A and B are each selected from

20



O, S, and SO<sub>2</sub>; and  
x+y+z is 0 to 16 but y is not 0 when n and m  
are both 1 and y must be greater than 2 when  
A and B are selected from O, S and SO<sub>2</sub>;

5 R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> are each a hydrogen or a  
(C<sub>1</sub>-C<sub>4</sub>) alkyl

or a pharmaceutically acceptable acid addition salt thereof.  
These compounds are potent MAO inhibitors and are useful in  
the treatment of Parkinson's and related syndromes and of  
depression.

10

As used herein the term alkyl group means both  
straight- and branched- chain alkyl group. (C<sub>1</sub>-C<sub>4</sub>) alkyl  
groups are methyl, ethyl, propyl, isopropyl, n-butyl,  
isobutyl, and tert butyl.

15 It will be apparent to those skilled in the art that,  
because the compounds of formula 1 contain one or more  
double bonds, geometric isomerism is possible. It should  
be understood, therefore, that in formula 1 the fluorine  
atom on the allylamine double bond can be oriented in the  
20 cis position or in the trans position. In naming compounds  
of formula 1 herein, the prefixes "(E)" and "(Z)" are used  
in the conventional manner to indicate the stereochemistry  
at the allylic double bond. If no stereochemical  
designation is given, both the substantially pure isomers,  
25 or mixtures thereof, are meant.

The primary nitrogen of the allyl amine group can be substituted with a ( $C_1-C_4$ ) alkyl group. These secondary amines are considered to be equivalent to the unsubstituted primary amines of Formula 1. The substituted compounds can  
5 be prepared by conventional N-alkylation methods. For example, the N-ethyl derivatives can be made by treating the primary amine with benzaldehyde in a lower alcohol (e.g. ethanol) to form the Schiff base, treating the Schiff base with triethyloxonium tetrafluoroborate, and  
10 hydrolyzing the intermediate thus formed.

The expression "pharmaceutically acceptable acid addition salts" is intended to apply to any non-toxic organic or inorganic acid addition salts of the base compounds represented by formula 1. Illustrative inorganic acids which form suitable salts include hydrochloric, hydrobromic, sulphuric and phosphoric acid and acid metal salts such as sodium monohydrogen orthophosphate and potassium hydrogen sulfate. Illustrative organic acids which form suitable salts include the mono, di and  
15 tricarboxylic acids. Illustrative of such acids are, for example, acetic, glycolic, lactic pyruvic, malonic, succinic, glutaric, fumaric, malic, tartaric, citric, ascorbic, maleic, hydroxymaleic, benzoic, hydroxybenzoic, phenylacetic, cinnamic, salicylic, 2-phenoxybenzoic and  
20 sulfonic acids such as methane sulfonic acid and 2-hydroxyethane sulfonic acid. Such salts can exist in either a hydrated or a substantially anhydrous form. In general, the acid addition salts of these compounds are crystalline materials which are soluble in water and  
25 various hydrophilic organic solvents and which, in comparison to their free base forms, generally demonstrate higher melting points and an increased chemical stability.  
30

Illustrative examples of the compounds of formula I  
are:

- 2-isobutyl-3-fluoroallylamine,
- 2-isopropyl-3-fluoroallylamine,
- 5 2-(9-octadecenyl)-3-fluoroallylamine,
- 2-(3-methyl-3-butenyl)-3-fluoroallylamine,
- 2-(4-methoxy-2-butenyl)-3-fluoroallylamine,
- 2-isobutylsulfonylmethyl-3-fluoroallylamine,
- 2-sec-butyl-3-fluoroallylamine,
- 10 2-butyl-3-fluoroallylamine,
- 2-hexyl-3-fluoroallylamine,
- 2-heptyl-3-fluoroallylamine,
- 2-ethoxymethyl-3-fluoroallylamine, and
- 2-thioethoxymethyl-3-fluoroallylamine

- 15 Preferred compounds of this invention are those formula I compounds wherein n and m are both zero, or wherein n and z are both zero and m is one with B being oxygen or sulfur. Also preferred are those formula I compounds wherein x + y + z is 0 to 4 and those compounds
- 20 wherein R is hydrogen or methyl. The preferred compound of this invention is 2-isobutyl-3-fluoroallylamine, more preferably its "E" isomer.

- 25 The compounds of formula I can be prepared by a variety of procedures readily apparent to those skilled in the art. For example the compounds of formula I wherein z≠0 can be prepared in a manner analogous to that described in U.S. Patent No. 4,454,158 or in McDonald, et al., J. Med Chem., 28, 186 (1985). The compounds of formula I wherein z=0 and B is O, S or SO<sub>2</sub> can be prepared in a manner
- 30 analogous to that described in European Patent Application 85108443.4 and in I. McDonald and P. Bey, Tet. Letters, 26, 3807 (1985).

In practice the compounds of this invention wherein z ≠ 0 are prepared by first preparing formula 2 diester



5 wherein

R' is  $\text{CH}_3-(\text{CH}_2)_x-\text{A}_n-(\text{CH}_2)_y-\text{B}_m-(\text{CH}_2)_z-\text{CHR}$ - or its functional equivalent

R<sub>a</sub> is tert-butyl, benzyl, diphenylmethyl, or triphenylmethyl; and

10 R<sub>b</sub> is a (C<sub>1</sub>-C<sub>4</sub>) alkyl, benzyl, diphenylmethyl or triphenylmethyl.


This diester is then treated with a strong base. The strong base must be nonnucleophilic and of sufficient strength to remove the proton on the methine moiety  
 15 adjacent to the carboxy groups. Suitable bases are known in the art. Examples are (a) an alkyl lithium (e.g. n-butyllithium), (b) an aryl lithium (e.g. phenyllithium), (c) a lithium dialkylamide (e.g. lithium diisopropylamide), (d) sodium or lithium amide, (e) a metal hydride (e.g.  
 20 sodium or potassium hydride), (f) metal alcoholate (e.g. sodium or potassium tert-butoxide), or (g) lithium or dilithium acetylidyde. The reaction between the diester and the base can be performed in an aprotic organic solvent (such as tetrahydrofuran (THF), diethyl ether,  
 25 dimethylformamide (DMF), dimethyl sulfoxide (DMSO), dimethoxyethane, or dioxane, or mixtures thereof), using a temperature range of about 0° to 70°C., preferably room temperature, and a reaction time of about 5 minutes to 2 hours. Preferred bases for forming the carbanion are  
 30 sodium hydride in dimethoxyethane, potassium tert-

butoxide/n-butyllithium in THF, or sodium tert-butoxide in THF.

By the term, a functional equivalent of  $\text{CH}_3-(\text{CH}_2)_x-\text{A}_n-$   
 $(\text{CH}_2)_y-\text{B}_m-(\text{CH}_2)_z-\text{CHR}-$  is meant a group which can be  
5 converted to a chain with the desired values of x, y, z, n,  
m, A and B. A functional equivalent can be used to prepare  
any of the formula 1 compounds but is most advantageously  
used where a desired value of x, y, z, n, m, A or B would  
interfere with the various reactions necessary to construct  
10 the fluoroallylamine moiety. The use of such functional  
equivalents will be readily apparent to those skilled in  
the art and will be exemplified below.

The anions of the formula 2 diesters are then treated  
with a halomethylating agent such as  $\text{CHClF}_2$ ,  $\text{CHBrF}_2$  and  
15  $\text{CHF}_2\text{I}$ . The halomethylation of the carbanion of a formula 2  
diester can be carried out *in situ* by adding the  
appropriate halomethylating agent to the anion at a  
temperature range of about  $0^\circ$  to  $70^\circ \text{ C}$  and allowing the  
reaction to proceed for about 1 to 24 hours, preferably  
20 about 1-2 hours. Depending upon the reactivity of the  
reactants, the halomethylating agent can be introduced at a  
higher temperature (about  $40^\circ \text{ C}$ ), and the reaction mixture  
can be allowed to cool to room temperature to complete the  
reaction or the halomethylating agent can be introduced at  
25 room temperature.

The resulting fluorinated diester of formula 3




wherein R', R<sub>a</sub> and R<sub>b</sub> are as defined above is then cleaved by acid hydrolysis or by catalytic hydrogenation to convert either one or both of the ester groups (-COOR<sub>a</sub> or -COOR<sub>b</sub>) to a free carboxylic acid group. Whether cleavage of one or both ester groups occurs will depend upon the nature of each ester group and the conditions employed for the cleavage reaction. In order to effect cleavage of only one ester group, it is preferred that the diester be mixed, the groups defined by R<sub>a</sub> and R<sub>b</sub> being chosen so that the ester group -COOR<sub>a</sub> can be selectively cleaved without cleaving the ester group -COOR<sub>b</sub>. The selection of particular ester groups which can be selectively cleaved and methods for performing the selective cleavage will be apparent to those skilled in the art. To accomplish selective cleavage of the diester, it is preferred to employ a mixed diester wherein R<sub>a</sub> is tert-butyl, benzyl, diphenylmethyl, or triphenylmethyl and R<sub>b</sub> is a straight-chain (C<sub>1</sub>-C<sub>4</sub>) alkyl group (such as methyl, ethyl, propyl, or n-butyl).

The ester group defined by -COOR<sub>a</sub> can be selectively hydrolyzed by treatment with an organic or inorganic acid, either with or without an added solvent, using a temperature range of about 0° to 25°C, and a reaction time of about 1 to 10 hours. Ambient temperature is preferred. The choice of the acid for the hydrolysis is not critical, except that the acid should be chosen so that it can be easily removed after the hydrolysis stage. Trifluoroacetic acid is preferred since its low boiling point permits it to be easily removed from the hydrolysis product. When R<sub>a</sub> is benzyl, diphenylmethyl, or triphenylmethyl and R<sub>b</sub> is a straight-chain (C<sub>1</sub>-C<sub>4</sub>) alkyl group, the ester group -COOR<sub>a</sub> can also be selectively cleaved by subjecting the mixed diester to catalytic hydrogenolysis using conventional procedures, for example, by treatment under a hydrogen atmosphere in the presence of a catalyst (e.g. Pd/C) at

ambient temperature for 1 to 48 hours. As will be apparent to those skilled in the art, the ester groups can be chosen so that both groups can be cleaved simultaneously by acid hydrolysis or catalytic hydrogenolysis. Thus, when it is 5 desired to cleave both ester groups simultaneously, each of R<sub>a</sub> and R<sub>b</sub> should be a tert-butyl, benzyl, diphenyl, or triphenylmethyl group.

The resulting acid obtained by cleavage of the diester (either a diacid or a mixed acid-ester) is treated with a 10 base whereby the acid undergoes decarboxylation and elimination of halide ion to afford the acrylic acid or the acrylate ester of formula 4




(4)

15 wherein R' is as defined above and R<sub>c</sub> is a hydrogen or a (C<sub>1</sub>-C<sub>4</sub>) alkyl. Whether the product is an ester (R<sub>c</sub> is a straight-chain C<sub>1</sub>-C<sub>4</sub> alkyl group) or an acid (R<sub>c</sub> is hydrogen) depends upon whether the cleavage reaction in the first stage was performed selectively or non-selectively. 20 The reaction can be performed using an aqueous or non-aqueous solvent. Strong bases, such as sodium hydroxide and the like, or weak bases, such as triethylamine or sodium bicarbonate, can be used. However, with strong bases, care must be taken to avoid using an excess of base 25 to avoid interaction with the double bond. Weak bases (which do not interact with the double bond) can be used in excess. The choice of a particular base, the reaction solvent, and reaction conditions will be apparent to those skilled in the art. A preferred procedure is to employ


aqueous sodium hydroxide in THF at ambient temperature. In general, a temperature range of about 0° to 25°C. and reaction time of 15 minutes to 2 hours can be used.

The acrylic acid or acrylate ester of formula 4 is  
 5 reduced to yield the allyl alcohol of formula 5.




wherein R' is as defined above. The reducing agent employed for this transformation can be any reagent which  
 10 is known in the art to be capable of selectively reducing an ester function or carboxylic acid function to the corresponding carbinol in the presence of a double bond. A preferred reducing agent is diisobutylaluminium hydride (DIBAL-H\*) in hexane, THF, diethyl ether, or  
 15 dichloromethane, or mixtures thereof. In a preferred procedure, a solution of the acrylate methyl ester in THF is cooled to about 0° to -78°C. (preferably -60° to -70°C.), the DIBAL-H\* dissolved in hexane is added, and the temperature of the mixture is allowed to rise to ambient.  
 20 The reaction time can be about 2 to 24 hours.

The allyl alcohol of formula 5 can be converted to the desired allyl primary amine using procedures known in the art to be useful for replacing an allylic hydroxyl group by an allylic primary amino group. A preferred laboratory  
 25 method involves the direct formation of an imido derivative of formula 6



5 wherein R' is as defined above and W is



and subsequent cleavage of the imido group to generate the primary amino group.


10 The formula 6 imido group can be conveniently prepared by treating the formula 5 allyl alcohol with the appropriate imide (i.e. phthalimide, succinimide, or maleimide) in the presence of a triarylphosphine (e.g. triphenylphosphine) or a trialkylphosphine and diethyl azodicarboxylate in an aprotic organic solvent (e.g. THF or dioxane). The reaction can be performed using a temperature range of about 0° to 70°C and a reaction time of about 1 to 24 hours. Ambient temperature is preferred. Subsequently the imido derivatives of structure 8 can be cleaved, preferably by reaction with hydrazine in an 15 organic solvent, such as an alkanol (e.g. ethanol), at reflux temperature (50° to 100°C.) and a reaction time of about 30 minutes to 10 hours. It is preferable to add an acid (e.g. hydrochloric acid) after the hydrazine treatment to convert the product to the acid addition salt. Other 20 reagents can be used to cleave the imido function. For 25

example, the imide can be heated with a strong mineral acid (e.g. hydrochloric or sulfuric acid) or a mixture of hydrochloric acid and acetic acid. Acids, such as hydrobromic acid, which are reactive towards olefins 5 usually cannot be used. The final products of structure 1 are conveniently purified and isolated as the acid addition salt using conventional purification methods.

In those instances wherein B is a O, S or  $\text{SO}_2$  group and wherein z is zero, R' is preferably a functional 10 equivalent such as a halomethyl group, for example, chloromethyl or bromomethyl. The formula 6 imido derivative wherein R' is a halomethyl group can advantageously be converted to the desired chain having the desired values of x, y, z, n, m, A and B at this stage by 15 forming the appropriate alkoxide or thiolate anion and allowing this anion to react with the formula 6 compound wherein R' is a halomethyl. Where it is desired that B have the value  $\text{SO}_2$ , oxidation of the corresponding compound wherein B is a sulfur atom is an alternate method of 20 preparation.

The allyl alcohol of formula 5 can also be converted to the allyl primary amine via formation of the reactive intermediate of formula 7

25



wherein R' is as defined above and Q is chlorine, bromine, iodine, benzenesulfonyloxy, p-toluenesulfonyloxy (tosyloxy), methylsulfonyloxy (mesyloxy), or other good 30 leaving group, in which the -OH group is replaced by a

leaving group, Q. Suitable leaving groups are known in the art. For example, chlorine, bromine, iodine, tosyloxy, or mesyloxy can be employed. Methods for replacing the hydroxy group by the leaving group are known in the art.

- 5 For example, the allyl alcohol of formula 5 can be treated with a phosphorus trihalide (e.g.  $\text{PCl}_3$  or  $\text{PBr}_3$ ) in an organic solvent, such as toluene or benzene, to introduce halogen (e.g. chlorine or bromine). The allyl alcohol can also be treated with a tosyl halide or mesyl halide (e.g.
- 10 tosyl chloride or mesyl chloride) in the presence of a base (e.g. pyridine) to introduce the tosyloxy or mesyloxy group. The reactive intermediate of formula 7 can be converted to the allyl primary amine of formula 8 in a known manner by displacement of the leaving group (Q)
- 15 either directly by ammonia or by a nucleophilic group (B) which can then be cleaved to generate the primary amino group. Examples of groups defined by B which can be used to generate a primary amino group are the hexamethylenetetrammonium group, an imido group (e.g.
- 20 phthalimido, succinimido, or maleimido group) or an alkylcarboxyamino group of the formula:



wherein  $\text{R}_d$ , is  $(\text{C}_1-\text{C}_4)$ alkyl. The hexamethylenetetramonium group can be introduced by treating the reactive intermediate of formula 7 with hexamethylenetetramine in an organic solvent (e.g. a  $(\text{C}_1-\text{C}_4)$  alkanol or chloroform) using ambient temperature and a reaction time of about 30 minutes to 24 hours. The hexamethylenetetrammonium group can be cleaved to generate

- 25 the primary amino group by treatment with an aqueous acid (e.g. hydrochloric acid) under reflux. Acids which are reactive to the double bond cannot be used. The imido group can be introduced by treating the reactive
- 30

intermediate of formula 7 with the appropriate alkali metal imide (e.g. sodium or potassium phthalimide, succinimide, or maleimide) in an organic solvent, such as tetrahydrofuran (THF), dimethylformamide (DMF),  
 5 dimethylsulfoxide (DMSO), or dioxane using a temperature range of about 0° to 70°C., preferably ambient temperature, and a reaction time of about 30 minutes to 12 hours, preferably 3 hours. The imido group can be cleaved to generate the primary amino compound of formula 8

10



wherein R' is as defined above

using the methods described supra with respect to the cleavage of the formula 6 compounds.

15 The alkylcarboxyamino group ( $-\text{NHCO}_2\text{R}_d$ ) can be introduced by treating the reactive intermediate with an alkali metal cyanate (e.g. sodium or potassium cyanate) and a ( $\text{C}_1-\text{C}_4$ ) alkanol using a temperature range of about 70° to 150°C, preferably 100°C, and a reaction time of about 1 to  
 20 6 hours, preferably 2 hours. The alkylcarboxyamino group can be cleaved to generate the primary amino group by treatment with iodotrimethylsilane followed by hydrolysis. The reaction with iodotrimethylsilane is performed in an organic solvent (e.g. chloroform) using a temperature range  
 25 of about 0° to 100°C., preferably 50°C., and a reaction time of about 1 to 24 hours, preferably 1 to 2 hours.


It should be apparent that the above-described decarboxylation and halide ion elimination from the diacid or mixed acid ester derivative of a formula 3 compounds  
 30 gives a formula 4 acrylic acid or ester having geometric isomerism about the resulting allylic carbon-carbon double

bond. Substantially all of the product is that geometric isomer in which the fluorine located on the double bond is cis to the group represented by R'. When the other geometric isomer is desired, the above-described procedure 5 is used to prepare the formula 6 imido derivative wherein the fluorine and R' group are cis to one another, and subsequently halogenating the double bond followed by a dehalogenation to re-introduce the double bond but wherein the fluorine and R' group are trans to one another. This 10 isomeric conversion can be performed by, for example, reacting the "cis" formula 6 compound with bromine in methylene chloride in the absence of light followed by a debromination using potassium iodide in acetone. The resulting "trans" formula 6 compound can be converted to 15 the desired formula 8 compound as described above.


It should also be readily apparent that in those compounds wherein A or B contain an olefinic bond, this bond will be isomerized at the same time as will the olefinic bond of the allyl moiety. A suitable reactive 20 equivalent, R', for a formula 1 compound wherein A or B contains an olefinic bond and wherein the allylic double bond is to be isomerized, is that value of A or B wherein the olefinic bond is of the opposite configuration to that of the desired compound. Thus the bond isomerization 25 procedure will cause concurrent isomerization about both double bonds. Alternatively the reactive equivalent, R', will contain a functional protecting group for the olefinic bond of the A or B group. Olefinic functional group protection is well known to those skilled in the art.

30 The diesters of formula 2 are either known compounds or they can be prepared from known compounds using known methods or obvious modifications thereof. In particular,

the diesters can be made by acylating an appropriate carboxylic acid ester of formula 9a or 9b.




5 (9a)




(9b)

wherein R', R<sub>a</sub> and R<sub>b</sub> are as defined above.

Methods of acylating the esters of formula 9a or 9b are known in the art. One method is to treat the ester with a non-nucleophilic strong base to produce the 10 carbanion, and then to treat the carbanion with a suitable acylating agent. Suitable strong bases are known in the art, and are discussed with respect to forming the anion of a formula 2 diester above. A preferred base is lithium diisopropylamide. Any conventional acylating agent can be 15 employed. A preferred acylating agent is a reactive halide of a formic acid alkyl ester, as shown in formula 10a and 10b



(10a)




(10b)

20 wherein R<sub>a</sub> and R<sub>b</sub> are as defined above and Hal is chlorine or bromine. In a preferred acylation procedure, an ester of formula 9a or 9b is treated with a base (e.g. lithium diisopropylamide) in an organic solvent (e.g. THF, dimethyl ether, acetonitrile, DMF, DMSO, or dioxane) at a low 25 temperature (e.g. about -30° to -78°C., preferably -65° to -78°C). The reaction can be allowed to proceed for a

period of from 5 minutes to 2 hours, preferably about 1 hour. The acylation reaction can be performed by adding the haloformate ester to the cooled reaction mixture containing the carbanion and allowing the mixture to warm 5 to room temperature. The acylation is allowed to continue for a period of about 4 to 24 hours, preferably 16 hours.

The diesters of formula 2 can be made by an alternative method. In this method, a malonic acid diester of formula 11



(11)

wherein  $R_a$  and  $R_b$  have the meanings given above is alkylated using an alkylating agent of formula 12



15 (12)

wherein  $R'$  and  $Q$  have the meaning given above. The alkylation is performed in two stages, the first being treatment with a strong base to form the carbanion, and the second being the treatment of the carbanion with the 20 alkylating agent. Methods for carrying out malonic acid ester alkylation are discussed supra and are well known in the art.

The compounds produced by the foregoing processes may be isolated either per se or as acid addition salts 25 thereof. A resulting acid addition salt may be converted into the free compound according to known methods, for example, by treating it with an alkali or alkaline earth

metal hydroxide or alkoxide; with an alkali metal or an alkaline earth metal carbonate or hydrogen carbonate; with trialkylamine; or with an anion exchange resin.

A resulting acid addition salt may also be converted  
5 into another acid addition salt according to known methods;  
for example, a salt with an inorganic acid may be treated  
with sodium, barium or silver salt of an acid in a suitable  
diluent, in which a resulting inorganic salt is insoluble  
and is thus removed from the reaction medium. An acid  
10 addition salt may also be converted into another acid  
addition salt by treatment with an anion exchange  
preparation.

The compounds of formula 1 are pharmacologically active, being capable of inhibiting MAO in vitro and in  
15 vivo. They are useful for the treatment of psychiatric disorders, in particular depression, which are known to be responsive to MAO inhibitor therapy and are useful in the treatment of Parkinson's syndrome. For the treatment of depression, the compounds can be employed in a manner  
20 similar to that of the known clinically active MAO inhibitors, such as phenelzine and tranylcypromine.

Surprisingly, many of the compounds of formula 1 are capable of preferentially inhibiting the B form of MAO in vitro and, at suitable low dosages in vivo, such compounds  
25 will inhibit MAO-B without substantially inhibiting MAO-A. At dosage levels where such compounds exert a selective effect on MAO-B, the compounds will not produce a marked "cheese effect". Hence, as with L-deprenyl, a known selective inhibitor of MAO-B, such compounds can be  
30 employed at suitable dosages for the treatment of depression, or for the potentiation of L-DOPA in the treatment of Parkinsonism, with a significantly decreased

risk of producing side effects, such as the "cheese effect".

When employed to treat depression, the effective dosage of the compounds of formula 1 will vary according to 5 the particular compound being employed, the severity and nature of the depression and the particular subject being treated. In general, effective results can be achieved by administering a compound at a dosage level from about 5 mg to about 100 mg per day, given systemically. Therapy 10 should be initiated at lower dosages, the dosage thereafter being increased until the desired effect is obtained.

As mentioned above the compounds of formula 1 are also useful for the treatment of Parkinson's syndrome when administered in combination with exogenous dopa, in 15 particular L-dopa and a peripherally acting decarboxylase inhibitor such as carbidopa. The co-administration of a compound of formula 1 with L-dopa potentiates the effect of L-dopa and thereby provides effective therapy of Parkinsonism using substantially lower doses of L-dopa 20 resulting in a decrease in side effects. The compounds of formula 1 potentiate L-dopa by preventing the oxidative deamination of dopamine by the monoamino oxidase enzyme in the brain.

In order to potentiate the therapeutic effects of L- 25 dopa in the treatment of Parkinsonism, the dosage of a compound of formula 1 must be effective to block the oxidation of dopamine centrally. The effective dosage will vary according to the particular compound employed, the relative amount of co-administered L-dopa, the route of 30 administration, and the severity of the symptoms being treated. Therapy should be initiated at lower dosages, the dosage thereafter being increased until the desired potentiation of L-dopa is achieved.

When employed to treat Parkinson's syndrome alone, L-dopa is administered initially at a dose of from 0.1 to 1 g daily, after which the amount administered is gradually increased over a 3 to 7 day period to a maximum tolerated 5 daily dose of about 8 grams (given in divided doses). By co-administering a compound of formula 1 with L-dopa, the dosage of L-dopa administered can be reduced 2-10 fold, as compared to the dosage of L-dopa alone. In general, the amount of the compound of formula 1 as compared to the 10 amount of L-dopa administered will vary from about 1:2 to 1:500.

It will be understood that a compound of formula 1 can be co-administered with L-dopa either substantially at the same time as or prior to the administration of L-dopa.

15 When administered prior, the compound can be given up to 4 hours prior, depending on the route of administration and severity of the condition being treated.

When used in combination with exogenous L-dopa, a compound of formula 1 can be administered in unit dosage 20 form, either in formulations containing the compound as the sole active agent or in formulations containing both the compound and L-dopa as active agents. In either mode of administration, the amount of compound of formula 1 administered as compared to the amount of L-dopa 25 administered, will vary from 1:1 to 1:500, depending upon the compound employed.

At dosage levels set forth above, the compounds of formula 1 will, in general, inhibit both forms of MAO. However, at low dosage levels, they will preferentially 30 inhibit MAO-B and have a decreased risk of producing the "cheese effect". Thus, for example, 2-isobutyl-3-fluoroallylamine, 2-butyl-3-fluoroallylamine or 2-hexyl-3-

fluoroallylamine will selectively inhibit MAO-B at a systemic dosage range of about 0.1 mg to about 5 mg per day. At this dosage range, the risk of adverse reaction from the "cheese effect" will be substantially reduced or  
5 eliminated.

The active compounds of this invention can be administered in various manners to achieve the desired effect. The compounds can be administered alone or in combination with pharmaceutically acceptable carriers or  
10 diluents, the proportion and nature of which are determined by the solubility and chemical properties of the compound selected, the chosen route of administration, and standard pharmaceutical practice. The compounds may be administered orally in solid dosage forms, e.g. capsules, tablets,  
15 powders, or in liquid forms, e.g. solutions or suspensions. The compounds may also be injected parenterally in the form of sterile solutions or suspensions. Solid oral forms may contain conventional excipients, for instance, lactose, sucrose, magnesium stearate, resins, and like materials.  
20 Liquid oral forms may contain various flavoring, coloring, preserving, stabilizing, solubilizing, or suspending agents. Parenteral preparations are sterile aqueous or nonaqueous solutions or suspensions which may contain certain various preserving, stabilizing, buffering, solubilizing, or  
25 suspending agents. If desired, additives, such as saline or glucose may be added to make the solutions isotonic.

The amount of active compound administered will vary and can be any effective amount. Unit doses of these compounds can contain, for example, about 5 mg to about 100  
30 mg of the compounds and may be administered, for example, one or more times daily, as needed.

The term "unit dosage form" is used herein to mean a single or multiple dose form containing a quantity of the active ingredient in admixture with or otherwise in association with the diluent or carrier, said quantity being such that one or more predetermined units are normally required for a single therapeutic administration. In the case of multiple dose forms such as liquids or scored tablets, said predetermined unit will be one fraction such as 5 ml (teaspoon) quantity of a liquid or a half or quarter of a scored tablet, of the multiple dose form.

In the composition aspect of the invention, there are provided pharmaceutical formulations in which form the active compounds of the invention will normally be utilized. Such formulations are prepared in a manner well known per se in the pharmaceutical art and usually comprise at least one active compound of the invention in admixture or otherwise in association with a pharmaceutically acceptable carrier or diluent therefore. A carrier or diluent may be solid, semi-solid, or liquid material which serves as a vehicle, excipient, or medium for the active ingredient. Suitable diluents or carriers are well known per se. The pharmaceutical formulations may be adapted for enteral or parenteral use and may be administered to the patient in the form of tablets, capsules, suppositories, solutions, suspensions or the like.

The invention is illustrated in the following non-limiting Examples.

EXAMPLE 1tert-Butyl 4-Methylvalerate

A solution of 4-methylvaleric acid (25 g) in tert-butyl acetate (538 ml) is treated with perchloric acid (2.7  
5 ml) then stirred at ambient temperature for 1.5 h. This is subsequently poured into water (350 ml) containing NaOH (50g) and the tert-butyl ester is isolated by ether extraction as a pale yellow oil (24.90g; 68% yield).

10 NMR(CDCl<sub>3</sub>) δ 0.88(d, J=6Hz, 6H), 1.45(m, 12H), 2.20 (t,  
J=7.5Hz, 2H).

EXAMPLE 2Ethyl 2-(tert-Butoxycarbonyl)-4-methylvalerate

A solution of lithium diisopropylamide is prepared from diisopropylamine (29.02g) and 1.6M n-butyl lithium  
15 (183.5 ml) in THF (45 ml). This is cooled to -78°C and a solution of tert-butyl 4-methylvalerate (24.67g) in THF (45 ml) is added slowly. After 1 hour a solution of ethyl chloroformate (15.56 g) in THF (45 ml) is added and stirring is continued at ambient temperature for 24 hours.  
20 The mixture is then poured into water, neutralized with dilute aqueous HCl and the product isolated by ether extraction. In this way the crude malonate is obtained as an orange oil (35.57 g).

25 NMR(CDCl<sub>3</sub>) δ 0.85 to 1.78 (m, 21H), 3.27 (t, J=7.5Hz, 1H),  
4.17 (q, J=7Hz, 2H).

EXAMPLE 3Ethyl 2-(tert-Butoxycarbonyl)-2-(difluoromethyl)-4-methylvalerate

Solid sodium tert-butoxide (27.73 g) is added to a  
5 solution of crude ethyl 2-(tert-butoxycarbonyl)-4-methylvalerate (35.37 g) in THF (300 ml). The mixture is stirred for 1 hour then heated to 45°C at which time Freon 22 ( $\text{ClCHF}_2$ ) gas is added rapidly for about 10 minutes. Stirring is continued for 1 hour under an atmosphere of  
10 Freon 22 during which time the temperature falls to ambient. The reaction mixture is poured into water/brine and the crude product is isolated as an orange oil (35.89 g) by ether extraction.

NMR( $\text{CDCl}_3$ )  $\delta$  0.83 to 2.00 (m, 21H), 4.23 (q,  $J=7\text{Hz}$ , 2H),  
15 6.23 (t,  $J=54\text{Hz}$ , 1H).

EXAMPLE 4(E)-Ethyl 2-Isobutyl-3-fluoroacrylate

A solution of ethyl 2-(tert-butoxycarbonyl)-2-(difluoromethyl)-4-methylvalerate (35.68 g) in  
20 trifluoroacetic acid (243 ml) is stirred for 1 hour, then the excess trifluoroacetic acid is removed by evaporation. The residual oil (30.89 g) is dissolved in THF (400 ml) and treated slowly with M NaOH (121 ml) so that the pH does not rise above 7.02. After completion of the addition the  
25 solution is stirred for another 15 minutes and the product

is extracted into ether. Careful distillation at atmospheric pressure, then at 24mm allows the separation of essentially pure acrylate as a colorless oil (5.72 g), bp 70-72°C.

5 NMR(CDCl<sub>3</sub>) δ 0.90 (d, J=6Hz, 6H), 1.27 (t, J=7Hz, 3H), 1.37 to 2.30 (m, 3H), 4.18 (q, J=7Hz, 2H), 7.57 (d, J=83Hz, 1H).

#### EXAMPLE 5

##### (E)-2-Isobutyl-3-fluoroallyl Alcohol

A solution of the acrylate (5.60 g) in hexane (172 ml)  
 10 cooled to -10° is treated slowly with a solution of diisobutylaluminum hydride in hexane (1M solution, 96.5 ml). The solution is stirred at ambient temperature for 90 minutes, then cooled to 10°C and treated consecutively with CH<sub>3</sub>OH (96.5 ml) and 6M aqueous HCl (138 ml). Water is added  
 15 and the product is isolated by ether extraction followed by careful distillation of the solvents to leave almost pure alcohol (7.0 g) contaminated with some residual hexane.

NMR(CDCl<sub>3</sub>) δ 0.93 (d, J=6Hz, 6H), 1.45 to 2.17 (m, 3H), 2.03 (s, 1H), 3.98 (d, J=4Hz, 2H), 6.67 (d, J=85Hz, 1H).

20

#### EXAMPLE 6

##### (E)-1-Fluoro-2-Isobutyl-3-phthalimidopropene

A solution of the crude alcohol (7.0g), potassium phthalimide (4.41g) and triphenylphosphine (7.80g) in THF

(200 ml) is cooled to 0°C and treated slowly with a solution of diethyl azodicarboxylate (5.22g) in THF (70 ml). Stirring is continued at ambient temperature overnight, then the solution is evaporated to leave an 5 orange paste (15 g). Chromatography on silica (20% ether in petroleum ether as eluant) allows the separation of pure phthalimide (4.25 g), mp 57-60°C.

NMR(CDCl<sub>3</sub>) δ 0.92 (m, 6H), 1.95 (m, 3H), 4.13 (d,d,  
J=3.5Hz, 1.0Hz, 2H), 6.78 (d, J=84Hz, 1H), 7.80 (m, 4H).

10

EXAMPLE 7(E)-2-Isobutyl-3-fluoroallylamine

A mixture of the phthalimide (3.75 g) and hydrazine hydrate (1.08 g) in ethanol (250 ml) is refluxed for 2.5 hours. 6N aqueous HCl (12.5 ml) is added and the mixture 15 is evaporated to dryness. The residue is dissolved in water (50 ml), the pH is adjusted to 8 with NaHCO<sub>3</sub>, then a solution of di-tert-butyl dicarbonate (4.68 g) in chloroform (500 ml) is added. The mixture is refluxed for 2.5 hours then the crude N-BOC derivative is isolated by 20 CHCl<sub>3</sub> extraction. Purification is achieved by silica chromatography (40% methylene chloride in petroleum ether) whereupon pure material (1.20 g) is obtained as an almost colorless oil. This is dissolved in hydrogen chloride-saturated ether (25 ml), left overnight, then filtered to 25 give the hydrochloride salt of (E)-2-isobutyl-3-fluoroallylamine (0.46 g) as colorless plates; mp 179°C.

Analysis for C<sub>7</sub>H<sub>14</sub>FN.HCl

Found: C, 50.34, H, 8.87, N, 8.35%

Require: C, 50.15; H, 9.01, N, 8.35%

NMR ( $D_2O$ )  $\delta$  0.80 (d,  $J=7\text{Hz}$ , 6H); 1.50 to 2.10 (m, 3H); 3.44 (broadened s, 2H); 6.80 (d,  $J=83\text{Hz}$ , 1H).

According to this procedure the following compounds  
5 are prepared. In each case, the allylamine is reported as  
its hydrochloride salt.

(E)-2-Isopropyl-3-fluoroallylamine, prepared from  
isovaleric acid;

(E)-2-sec-Butyl-3-fluoroallylamine, prepared from 3-  
10 methylvaleric acid; mp 236°C

Analysis for  $C_7H_{14}FN \cdot HCl$

Found: C, 49.65; H, 8.72; N, 8.64%

Require: C, 50.15; H, 9.01; N, 8.35%

(E)-2-Butyl-3-fluoroallylamine, prepared from hexanoic  
15 acid; mp 141°C

Analysis for  $C_7H_{14}FN \cdot HCl$

Found: C, 50.17; H, 8.78; N, 8.31%

Require: C, 50.15; H, 9.01; N, 8.35%

(E)-2-Hexyl-3-fluoroallylamine, prepared from octanoic  
20 acid; mp 141°C

Analysis for  $C_9H_{18}FN \cdot HCl$

Found: C, 55.24; H, 9.00; N, 7.08%

Require: C, 55.23, H, 9.27; N, 7.15%

(E)-2-Heptyl-3-fluoroallylamine, prepared from nonanoic  
25 acid; mp 129°C

Analysis for  $C_{10}H_{20}FN \cdot HCl$

Found: C, 57.11; H, 9.70; N, 7.11%

Require: C, 57.27; H, 10.09; N, 6.67%

EXAMPLE 8Ethyl 2-(tert-Butoxycarbonyl)tridecanoate

A suspension of pentane-washed sodium hydride (4.36 g of a 50% oil dispersion) and tert-butyl, ethyl malonate (18.83 g) in THF (150 ml) is stirred at ambient temperature for 15 minutes, then cooled in an ice-salt bath. A solution of undecyl bromide (23.52 g) in THF (50 ml) is added and stirring is continued in the cold for 1 hour, then overnight at ambient temperature. Ether extraction is followed by distillation of remaining starting materials whereupon the residue is found to consist of the desired malonate with a small amount of dialkylated material.

EXAMPLE 9(E)-2-Undecyl-3-fluoroallylamine

Ethyl 2-(tert-butoxycarbonyl)tridecanoate is converted to the allylamine by following the procedure of Examples 3, 4, 5, 6, and 7, mp. 140°C.

Analysis for C<sub>14</sub>H<sub>28</sub>FN.HCl

Found: C, 63.17; H, 10.75; N, 5.25%  
Require: C, 63.25; H, 11.00; N, 5.27%.

NMR(D<sub>2</sub>O) 0.80 (m, 3H), 1.3 (m, 18H), 2.20 (m, 2H), 3.50 (d, J=3Hz, 2H), 6.93 (d, J=82Hz, 1H).

EXAMPLE 10(Z)-2-Isopropoxymethyl-3-fluoroallylamine

Solid 1-fluoro-2-bromomethyl-3-phthalimidopropene (0.60 g) is added to a previously prepared mixture of 5 isopropanol (0.12 g) and sodium hydride dispersion (96 mg of 55-60% oil dispersion) in dimethylformamide (10 ml) at room temperature. Stirring is continued for 3 hours, then brine is added and the product is isolated by ether extraction. This product is treated with hydrazine hydrate 10 (0.13 g) in ethanol (20 ml) under reflux for 3 hours. Dilute aqueous hydrochloric acid is added and the resulting mixture is washed with ethyl acetate, then the aqueous layer is concentrated to about 5 ml. The residual solution is treated with di-tert-butyl dicarbonate (0.44 g), sodium 15 chloride (1 g) and chloroform (20 ml). Then sufficient sodium bicarbonate is added to adjust the pH of the aqueous layer to about 8. The mixture is refluxed for 1 1/2 hours then the crude N-Boc derivative can be isolated by extractive work-up. Purification is achieved by silica 20 chromatography using ether/petroleum ether as eluent. Cleavage of the Boc protecting group (anhydrous hydrogen chloride in ether) affords (Z)-2-isopropoxymethyl-3-fluoroallylamine as its hydrochloride salt.

EXAMPLE 11(Z)-2-Thiopropoxymethyl-3-fluoroallylamine

Following the procedure described in Example 10 but replacing isopropanol with 1-propanethiol, (Z)-2-thiopropoxymethyl-3-fluoroallylamine is obtained as its hydrochloride salt.

EXAMPLE 12Inhibition of MAO - In vitro testing

The ability of a compound of structure 1 to inhibit MAO can be determined in vitro by the method of A.

5 Christmas et al., Br. J. Pharmacol. 45, 490 (1972) in partially purified mitochondria from rat brain using  $^{14}\text{C}$  o-tyramine or  $^{14}\text{C}$  phenethylamine and  $^{14}\text{C}$  5-HT as the substrate. The MAO inhibitory activity of a compound is expressed as the "IC<sub>50</sub>" value, which is the molar 10 concentration required to produce 50% inhibition of the enzyme. The IC<sub>50</sub> values for certain compounds of structure 1 were determined using the above-described method, and the results are set forth in Table I.

15 The selectivity of a compound of structure 1 with respect to inhibition of MAO-A and MAO-B can be determined by preparing mitochondria from rat brain by homogenation in phosphate buffer (0.1 M, pH 7.2) followed by differential centrifugation. The mitochondria are suspended in the same buffer, the test compound is added at the desired 20 concentration, and the system is incubated. At different time intervals, aliquots are taken and MAO activity is measured using  $^{14}\text{C}$  5-hydroxytryptamine (5HT; a preferred substrate for MAO-A) or  $^{14}\text{C}$ -phenethylamine (PEA; a preferred substrate for MAO-B) as the substrates. The 25 selectivity is expressed as the ratio of the inhibitory activity against MAO-B versus the inhibitory activity against MAO-A. (Zreika, McDonald, Bey, Palfreyman, J. Neurochem., 43, 448-454 (1984)).

The data shown in Table I demonstrate that the compounds tested are potent irreversible inhibitors of MAO and that many of the compounds are highly selective for MAO-B.

5

TABLE I

|    | <u>TEST COMPOUND</u>               | <u>IC<sub>50</sub> (M)</u> |                      | <u>MAO_B<br/>SELECTIVITY</u> |
|----|------------------------------------|----------------------------|----------------------|------------------------------|
|    |                                    | <u>PEA</u>                 | <u>5HT</u>           |                              |
|    | (E)-2-Isobutyl-3-fluoroallylamine  | $3 \times 10^{-8}$         | $2.3 \times 10^{-6}$ | 77                           |
| 10 | (E)-2-Butyl-3-fluoroallylamine     | $2 \times 10^{-9}$         | $1.1 \times 10^{-7}$ | 55                           |
|    | (E)-2-Hexyl-3-fluoroallylamine     | $7 \times 10^{-9}$         | $1.7 \times 10^{-7}$ | 24                           |
| 15 | (E)-2-Heptyl-3-fluoroallylamine    | $4.5 \times 10^{-9}$       | $6 \times 10^{-8}$   | 13                           |
|    | (E)-2-Isopropyl-3-fluoroallylamine | $2.5 \times 10^{-6}$       | $1.7 \times 10^{-4}$ | 68                           |
|    | (E)-2-sec-Butyl-3-fluoroallylamine | $7 \times 10^{-6}$         | $1.7 \times 10^{-4}$ | 24                           |
| 20 | (E)-2-Undecyl-3-fluoroallylamine   | $5 \times 10^{-7}$         | $7.5 \times 10^{-7}$ | 1.5                          |

EXAMPLE 13Inhibition of MAO-Ex vivo

The ability of a compound of formula 1 to inhibit MAO can be determined ex vivo by the following procedure:

5       The test compound is administered orally (po) to rats and the animals are killed at various times after treatment. The brain is removed and a mitochondrial fraction, described in Example 12 is prepared. MAO activity is determined using  $^{14}\text{C}$  p-tyramine, as the substrate. Selectivity can be determined by repeating the above-described test using either  $^{14}\text{C}$  5-hydroxytryptamine (for MAO-A) or  $^{14}\text{C}$  phenethylamine (for MAO-B) as the substrate for determining the % inhibition.

10      When (E)-2-Isobutyl-3-fluoroallylamine is tested in this way the  $\text{ED}_{50}$  is 0.05 mg/kg for MAO-B inhibition and 0.8 mg/kg for MAO-A inhibition.

EXAMPLE 14

An illustration composition of hard gelatin capsules 20 is as follows:

|     |                 |       |
|-----|-----------------|-------|
| (a) | Active compound | 5 mg  |
| (b) | Talc            | 5 mg  |
| (c) | Lactose         | 90 mg |

The formulation is prepared by passing the dry powders of (a) and (b) through a fine mesh screen and mixing them well. The powder is then filled into hard gelatin capsules at a net fill of 100 mg per capsule.

5

EXAMPLE 15

An illustrative composition for tablets is as follows:

|     |                        |       |
|-----|------------------------|-------|
| (a) | Active compound        | 5 mg  |
| (b) | Starch                 | 45 mg |
| (c) | Lactose                | 48 mg |
| 10  | (d) Magnesium stearate | 2 mg  |

The granulation obtained upon mixing the lactose with the compound (a) and the part of the starch and granulated with starch paste is dried, screened, and mixed with the magnesium stearate. The mixture is compressed into 15 tablets weighing 100 mg each.

EXAMPLE 16

An illustrative composition for an injectable suspension is the following 1 ml ampule for an intramuscular injection.

0224924


Weight per cent

|                                    |        |
|------------------------------------|--------|
| (a) Active compound                | 0.5    |
| (b) Polyvinylpyrrolidone           | 0.5    |
| (c) Lecithin                       | 0.25   |
| 5 (d) Water from injection to make | 100.00 |

The materials (a) - (d) are mixed, homogenized, and filled into 1 ml ampule which are sealed and autoclaved 20 minutes at 121°C. Each ampule contains 5 mg per ml of the active compound.

CLAIMS

1. A fluoroallylamine of the formula 1




wherein

R is hydrogen or a ( $\text{C}_1\text{-}\text{C}_4$ ) alkyl;

n and m are each either zero or 1;

A and B are each selected from



O, S and  $\text{SO}_2$ ;

x + y + z is 0 to 16 but y must be greater than 2 when A and B are each selected from O, S and  $\text{SO}_2$ ;

$\text{R}_1$ ,  $\text{R}_2$ ,  $\text{R}_3$ ,  $\text{R}_4$  and  $\text{R}_5$  are each a hydrogen or a ( $\text{C}_1\text{-}\text{C}_4$ ) alkyl or a pharmaceutically acceptable acid addition salt thereof.

2. A fluoroallylamine of claim 1 wherein n and m are both zero.

3. A fluoroallylamine of claim 1 wherein A or B is



4. A fluoroallylamine of claim 2 wherein x + y + z is 0 to 4.

5. A fluoroallylamine of claim 4 wherein R is hydrogen or methyl.

6. A fluoroallylamine of claim 1 wherein R is hydrogen, n is 1 and m is 0, A is  $\begin{array}{c} | \\ -\text{CH}- \\ | \\ \text{R}_1 \end{array}$ , x + y + z is 0 and  $\text{R}_1$  is methyl, that is the compound 2-isobutyl-3-fluoroallylamine.

7. A fluoroallylamine of claim 6 which is (E)-2-isobutyl-3-fluoroallylamine.

8. A fluoroallylamine of claim 1 wherein n and z are 0, R is hydrogen, B is O or S and x + y = 0 to 4.

9. A process for preparing a fluoroallylamine of formula 1 according to claim 1, which comprises reducing an acrylic acid or acrylate ester of formula 4



with a suitable reducing agent to produce an allyl alcohol of formula 5



which is then transformed into the desired product in a manner known per se.

10. The process of claim 9 wherein the reducing agent is diisobutylaluminum hydride and the reduction is carried out in hexane, tetrahydrofuran, diethylether or dichloromethane at from 0° to -78°C for from 2 to 24 hours.

11. A process of claims 9 or 10 wherein the allyl alcohol is transformed into the desired product by reaction with an imide, either a triarylphosphine or trialkylphosphine, and diethyl oxodicarboxylate in an aprotic organic solvent at from 0° to 70°C for from 1 to 24 hours and subsequently cleaving the resulting imido intermediate with hydrazine at a temperature of from 50° to 100°C for from 30 minutes to 10 hours.

12. A process of claims 9 or 10 wherein the allyl alcohol is transformed into the desired product by first treating with  $\text{PCl}_3$  or  $\text{PBr}_3$  or by treating with a tosyl or mesyl chloride in the presence of a base and subsequently treating with ammonia.

1        13. A compound according to any one of claims 1 to 8  
for use as a medicament.

5        14. A compound according to any one of claims 1 to 8  
for use in the treatment of Parkinson's and related syndromes  
and of depression.

10      15. A pharmaceutical composition comprising a compound  
according to any one of claims 1 to 8 and a pharmaceutically  
acceptable carrier.

15      16. A pharmaceutical composition for the treatment of  
Parkinson's syndrome comprising a compound according to any  
one of claims 1 to 8 and a pharmaceutically acceptable carrier.

15      17. A pharmaceutical composition according to claim 16,  
further comprising exogenous L-dopa.

20      18. A pharmaceutical composition according to any one  
of claims 16 and 17, further comprising a peripherally act-  
ing decarboxylase inhibitor.

25      19. A pharmaceutical composition according to claim 18,  
wherein the decarboxylase inhibitor is carbidopa.

25

30

35